EXENATIDE AS ADJUVANT THERAPY IN ISLET CELL TRANSPLANTATION

艾塞那肽作为胰岛细胞移植的辅助治疗

• 批准号: 7731301
• 负责人: ENRICO CAGLIERO
• 金额: $ 0.73万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7731301
• 关键词: Adjuvant Therapy; C-Peptide; Computer Retrieval of Information on Scientific Projects Database; Fasting; Funding; Glycosylated hemoglobin A; Grant; Institution; Insulin; Islets of Langerhans Transplantation; Label; Patients; Research; Research Personnel; Resources; Source; Testing; Transplantation; United States National Institutes of Health; blood glucose regulation; exenatide; glycemic control; improved; islet allograft; type I diabetic

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This pilot, open label trial aims at evaluating the efficacy of Exenatide as adjunctive therapy in type 1 diabetic patients, recipients of islet allografts that have fasting C-peptide levels of > 0.5 ng/ml but have been unable to maintain normal glucose control without exogenous insulin administration. Specifically, we plan to test the hypothesis that the use of Exenatide (10 mg sc tid) for a 6 month period in patients that have received al least 10,000 IE/kg with 1 or 2 transplants and are at least 6 months after the last transplant would result in improved glycemic control and permit the discontinuation of exogenous insulin therapy while maintaining HbA1c level < 7.0%.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 该试验性开放标签试验旨在评价Exenvitamin作为1型糖尿病患者的连续治疗的功效，所述患者是空腹C肽水平> 0.5ng/ml但在没有外源性胰岛素施用的情况下不能维持正常葡萄糖控制的胰岛同种异体移植物的接受者。具体而言，我们计划检验以下假设：在接受至少10，000 IE/kg、1次或2次移植且末次移植后至少6个月的患者中，使用艾塞那肽（10 mg sc tid）6个月将改善血糖控制，并允许停止外源性胰岛素治疗，同时维持HbA 1c水平<7.0%。